Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis

Cytokinetics Incorporated published this content on August 30, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 30, 2025 at 15:29 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]